MedPath

Efficacy of a shorter duration of prednisolone treatment for children in relapse with steroid sensitive nephrotic syndrome: A randomised controlled study

Phase 3
Conditions
Health Condition 1: null- Steroid Sensitive Nephrotic Syndrome
Registration Number
CTRI/2015/11/006345
Lead Sponsor
ICMR
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
114
Inclusion Criteria

1. Patients diagnosed with steroid sensitive nephrotic syndrome

2. Currently in relapse

3. Those who give written informed consent

Exclusion Criteria

1. Patients diagnosed with steroid resistant Nephrotic Syndrome

2. Patients with frequent relapses (defined as 2 or more relapses in 6 months or >3 in 12 months) or steroid dependence (defined as 2 consecutive relapses on alternate day therapy or within 2 weeks of discontinuation of therapy)

3. Known secondary cause (e.g. Hepatitis B, SLE, HSP)

4. Patients on alternate regimens with levamisole/cyclophospahmide/mycophenolate mofetil/azathioprine/rituximab

5. Patients who have not recieved atleast 4 weeks of daily steroids at 2 mg/kg followed by 4 weeks of 1.5 mg/kg alternate day steroids during initial episode

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of children becoming frequently relapsing nephrotic syndromeTimepoint: 0 and 12 months
Secondary Outcome Measures
NameTimeMethod
1. Time to first relpase <br/ ><br>2. Relapse rates <br/ ><br>3. Cumulative dose of steroids <br/ ><br>4. Adverse effects of steroidsTimepoint: 0, 1 mo, 3 mo, 6 mo, 9 mo, 12 mo
© Copyright 2025. All Rights Reserved by MedPath